Cost-effectiveness of abiraterone treatment in patients with castration-resistant prostate cancer who previously received docetaxel therapy

<p><strong>Background.</strong> Therapy for metastatic castration-resistant prostate cancer (CRPC) is a serious problem that requires significant public health care expenditures.</p><p><strong>Objective</strong>: to evaluate the cost-effectiveness of abirate...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: A. V. Rudakova, D. O. Meshkov, S. V. Mishugin
Format: Artigo
Langue:Russo
Publié: ABV-press 2014-11-01
Collection:Onkourologiâ
Sujets:
castration-resistant prostate cancer
chemotherapy
docetaxel
abiraterone
survival
cost effectiveness
Accès en ligne:http://oncourology.abvpress.ru/index.php/oncur/article/view/383
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires